# Chris Gay-Crosier

> Chris Gay-Crosier is a funding round investor at Verve Ventures backing Health Care. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Verve Ventures](https://shizune.co/investors/profile/verve-ventures)
- Location: Geneva, Switzerland
- Total investments: 1
- Last investment: Sep 2019
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/chris-gay-crosier-163b5382

Chris Gay-Crosier is a funding round investor at Verve Ventures in Geneva focused on Health Care and Therapeutics. As an investment manager, Chris is part of the Operations team. He identifies interesting investment opportunities, performs due diligence and manages investment rounds from start to finish.Chris received his Master’s degree in law from the University of St. Gallen. Prior to joining investiere, he did an internship at a law firm.Chris isinterested in history and enjoys travelling as well as outdoor sports.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 100% |
| Therapeutics | 1 | 100% |
| Biotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| PathoQuest | PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $8.8M |  | Sep 06, 2019 |  |

1 of 1 investments shown.

## Co-investors
- [Charles River Laboratories International](https://shizune.co/investors/profile/charles-river-laboratories-international) — VC Fund, 1 deal together
- [Fraser](https://shizune.co/investors/profile/fraser-finance) — VC Fund, 1 deal together
- [Idinvest Partners](https://shizune.co/investors/profile/idinvest-partners) — VC Fund, 1 deal together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 1 deal together
- [Norgine Ventures](https://shizune.co/investors/profile/norgine-ventures) — VC Fund, 1 deal together
- [Careismatic Brands](https://shizune.co/investors/profile/strategic-partners-2) — VC Fund, 1 deal together

## About Verve Ventures

VC Fund · Zug, Switzerland

Verve Ventures is a European startup investment platform for qualified and institutional investors. Their fully digital platform enables private investors to build a diversified portfolio with investments starting at CHF/EUR 10'000. Since its launch in 2010, Verve Ventures has invested more than EUR 130 million in over 100 startups. Theircommunity consists of 5’000 registered qualified private investors, family offices, and pension funds. Several institutional investors such as a large Swiss pension fund and numerous corporates also rely on their expertise to invest in promising startups. Verve Ventures is backed by Switzerland's third-largest bank, Zürcher Kantonalbank. They have a dedicated investment team based in Zurich, Lausanne, Berlin, Paris, and Cambridge, that screens thousands of startups each year and selects the top 1% after a rigorous due diligence process. They are reshaping the European venture capital landscape and granting investors superior access to this traditionally intransparent asset class. They source the best deals, and structure rounds, and enable their investors to participate in competitive startup deals.

5 contacts available at Verve Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Alexander Seel | Institutional clients | https://shizune.co/investors/profile/alexander-seel |
| Chris Gay-Crosier | Investment Manager | https://shizune.co/investors/profile/chris-gay-crosier-3b38 |
| Chris Gay-Crosier | Investment Manager | https://shizune.co/investors/profile/chris-gay-crosier |
| Lukas Weber | Co-Founder, Co-Chief Executive Officer & Chairman | https://shizune.co/investors/profile/lukas-weber |
| Michael Blank | Investment Manager | https://shizune.co/investors/profile/michael-blank-d1ca |

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Chris Gay-Crosier invest in?

Chris Gay-Crosier invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Funding Round stage. Most of the 1 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chris Gay-Crosier last invest?

The most recent investment recorded for Chris Gay-Crosier closed in Sep 2019. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co